These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25010761)

  • 1. [BOLERO -- another remarkable step in treatment of breast cancer].
    Rubovszky G; Láng I
    Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
    Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
    J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
    N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
    Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
    Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
    Beaver JA; Park BH
    Future Oncol; 2012 Jun; 8(6):651-7. PubMed ID: 22764762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
    Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
    Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
    Gilabert M; Launay S; Gonçalves A
    Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
    Vicier C; Dieci MV; Andre F
    Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
    Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
    Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
    Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
    André F; O'Regan R; Ozguroglu M; Toi M; Xu B; Jerusalem G; Masuda N; Wilks S; Arena F; Isaacs C; Yap YS; Papai Z; Lang I; Armstrong A; Lerzo G; White M; Shen K; Litton J; Chen D; Zhang Y; Ali S; Taran T; Gianni L
    Lancet Oncol; 2014 May; 15(6):580-91. PubMed ID: 24742739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
    Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
    J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.